Original Article
Pterygium Excision with
Adjunctive Subconjunctival Bevacizumab
Narain Das, Shakir Zafar, Asma Shams
Pak
J Ophthalmol 2018, Vol. 34, No. 3
. . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of
article for authors
affiliations …..……………………….. Correspondence
to: Narain Das MBBS, FCPS (Ophthalmology) Assistant Professor SMBBMC Lyari, Karachi E-mail: narainpagarani@yahoo.com |
Purpose: To analyze the efficacy of bevacizumab in
primary pterygium excision. Study Design: Randomized controlled clinical
trial. Place and Duration of Study: Study
was done at Shaheed Mohtarma Benazir Bhutto Medical College, Lyari General
Hospital, Karachi. Duration of study was six months from 15th
October, 2016 to 15th April, 2017. Material and Methods: 34 eyes of 34 patients (males 22,
females 12) with age range from 35 to 60 years (mean age of 45 years SD ± 12.2
years) were included. All patients of primary pterygium were selected and
divided into two groups, Group I underwent bevacizumab therapy (0.2 ml which
is equal to 5 mg) and Group II placebo (0.2 ml balanced salt solution) given
by sub conjunctival injection. After completing all necessary stages of
surgery, 0.2 ml (5 mg) bevacizumab was injected in the inferior fornix. All
patients were followed for 6 months. Postoperative complications and
recurrence were noted. Recurrence was defined as any fibrovascular extension
that passed the corneal limbus by more than 1 mm. Results: The average time for each procedure was 30 ±
10 minutes. During follow up period, the recurrence was noted in 5 patients.
2 eyes out of 17 (11.76%) in group I and 3 eyes out of 17 (17.64%) in group
II. Postoperative conjunctival vascularization occurred in 1 patient in group
I and 2 patients in group II and subconjunctival hemorrhage occurred in 4
patients in group I and 2 patients in group II while no other ocular
complications were observed in any group. Conclusion: Bevacizumab injection subconjunctivaly
showed statistically no significant effect on recurrence of pterygium and
having no significant adverse effects. Key Words: Subconjunctival injection, Bevacizumab,
Pterygium Excision. |
A pterygium is a triangular fibro vascular sub epithelial ingrowth
of degenerative bulbar conjunctival tissue over the limbus onto the cornea”.
Pterygium typically develops in patients who have been exposed to hot climates,
chronic dryness and ultraviolet radiations1. The pathogenesis of
pterygia is so far not known2,3. Various factors such as genetic and
many immunological factors play a vital role in the disease progression4,5.
Jin J et al expressed that pterygium contains increased levels of VEGF
and decreased levels of pigment epithelium-derived factor (PEDF) and angiogenic
inhibitor. This changed ratio leads to the development of pterygia6.
The treatment of pterygium is controversial since pterygium is
composed of proliferating fibro vascular tissue, its progression requires
neovascularization.7 Mitomycin-C, 5-fluorouracil, corticosteroids
and beta irradiations have been tried along with pterygium excision to prevent
recurrence of pterygia8,9. In the past, many aseptic techniques were
used for removal of pterygium such as horse hair and threads etc10.
Bevacizumab (Avastin; Roche, USA) is a recombinant humanized
monoclonal antibody. It is an inhibitor of VEGF, which interferes with the
growth of endothelial cells. This drug has been tried off-label in neovascular
ocular diseases with timely good results11-13.
Bevacizumab pharmacokinetics are quite different i.e. the dose
does not cause increase in efficacy but rather it increases its half-life 14.
This was the main reason behind the usage of 5 mg (Bevacizumab 3 times
level of normal dose) subconjunctivaly after primary excision of pterygium, as
there was altering data regarding its dose, the current study did not observe
any local or systemic side effect15-16.
After extensive literature search, the mechanism of action of
bevacizumab in pterygium is not well understood. However, the longest reported
duration of action is achieved via intravitreal route17.
MATERIAL AND METHODS
During the period of 15 October 2016 to 15 April 2017, this
randomized placebo controlled clinical trial study was conducted at the Shaheed
Mohtarma Benazir Bhutto Medical College Lyari (SMBBMCL) and Sindh Government
Lyari General Hospital. Written informed consent was taken from all the
patients. 34 eyes of 34 patients were selected and were randomly divided into
two groups, Group I (Bevacizumab) and Group II, Balanced Salt Solution (BSS). Pterygium
more than 3 mm involving visual axis causing decreased visual acuity or cosmetic
disfigurement were included in our study.
Patients with a history of myocardial infarction and vascular
thrombosis in the last six months and allergic to bevacizumab were excluded.
Patients with diabetes, pregnancy, lactation, glaucoma, regurgitation from
lacrimal puncta indicating nasolacrimal duct block, any ocular disease or
inflammation, autoimmune disorders and previous eye surgery were not included.
Following criteria for bevacizumab allergy assessment was applied.
1. All
patients were kept in ward for six hours after procedure for observing blood
pressure, hypersensitivity reactions such as localized flushes, urticaria,
dyspnoea and angioedema.
2. Hypertension
was managed with anti hypertensive e.g. calcium channel blockers after
consultation with physician.
3. Emergency
trolley containing Inj: Solucortef, Inj: Chlorpheniramine maleate, Inj:
Adrenaline, Airway Tube, Ambo bag, I/V Cannula /Normal Saline Drip, Disposable
Syringes and Hand Gloves were ready to deal with any emergency.
We recorded all patients’ demographic data, best-corrected visual
acuity, manifest refraction, keratometry reading, and intra ocular pressure by
Goldmann Applanation tonometer, detailed slit lamp examination including
horizontal length and grading of pterygium in mm and Fundus examination. All
patients were examined before and after surgery on each visit on day 1, 7, 30,
90 and 180. Post injection complications such as sub conjunctival hemorrhage, corneal
abrasion infection etc were analyzed if observed.
In both groups, excision of pterygium was done via conjunctival
flap method. Group I was injected with 5 mg / 0.2 ml (2.5 mg / 0.1 ml) of
bevacizumab and Group II was injected with 0.2 ml of BSS at the end of surgery.
Proparacaine HCl was used as a local anesthetic. Sub conjunctival
2% lidocaine with 1:100000 adrenaline was used in area of pterygium. After
completing all necessary stages of surgery, 0.2 ml, (5 mg) bevacizumab was
injected in the inferior fornix. Dexamethasone 1 mg and Moxifloxacin 5 mg was
given topically QID (Quarter in die) with Hydroxypropyl methyl cellulose QID
for 4 weeks.
RESULTS
The Study group comprised 34 eyes of 34 patients (males 22, females
12) with primary pterygium (there were 11 males and 6 females in each group).
There was no statistically significant difference regarding the age or gender
between the groups (P > 0.05). Visual acuity of all the patients in the
study after procedure was improved or maintained without further deterioration
of vision even in a single patient (Table 2).
The difference between the groups relating to pre operative visual
acuity, daily sun exposure, pterygium size and type, keratometric readings or
intra ocular pressure was not significant (P > 0.05). During follow up
period recurrence was noted in five patients, 2 eyes out of 17 (11.76%) in
group 1 and 3 eyes out of 17 (17.64%) in group 2 (Table 3).
Postoperative conjunctival vascularization occurred in three
patients (8.82%) out of 34 patients (1 in group I and 2 in groups II), which
was observed in the recurrent cases. Apart from sub conjunctival hemorrhage
which was seen in four patients in group I and two patients in group II, which
resolved within two weeks.
Table 1: Demographic data
of (34 patients).
|
|
Gender |
|
Eye |
|
Age |
No. & (%) of Patients |
Male |
Female |
Right |
Left |
< 45 years |
19 (55.8%) |
22 (64.7%) |
12 (35.3%) |
12 (35.3%) |
22 (64.7%) |
> 45 years |
15 (44.4%) |
|
|
|
|
Table 2: Comparison of the pre-operative and the
post-operative visual acuity of 34 eyes studied.
Visual
acuity |
Pre-operative
patients |
Post-operative
patients |
6/6 |
10 |
19 |
6/9 |
11 |
09 |
6/12 |
08 |
04 |
6/18 |
03 |
02 |
6/60 |
02 |
00 |
Table 3: Recurrence of pterygium between two groups.
Groups |
Total
Patients |
Recurrence |
Group I (Bevacizumab group) |
17 |
2 eyes (11.76%) |
Group II (BSS group) |
17 |
3 eyes (17.64%) |
No corneal abrasion, infection, persistent epithelial defect and
uveitis were noted after surgery (Table 4).
Table 4: Ocular
Complications.
Complications |
Group
I |
Group
II |
Total |
Sub conjunctival Hemorrhage |
04 |
02 |
06 |
Conjunctival Vascularization |
01 |
02 |
03 |
Ocular Surface Toxicity |
00 |
00 |
00 |
Corneal Abrasion |
00 |
00 |
00 |
Persistent Epithelial Defect |
00 |
00 |
00 |
Infection |
00 |
00 |
00 |
Uveitis |
00 |
00 |
00 |
DISCUSSION
Fibrovascular proliferation and inflammation play a pivotal role in
the pathogenesis of pterygium, which is a degenerative process. The extent and grade
of pterygium seem to predict recurrences after surgery quite reliably18.
Many immunological and genetic factors have been found in the progression
of the disease4,5. The development of pterygium depends upon the imbalance
of angiogenic and anti-angiogenic factors6. The findings of abundant
levels of VEGF in pterygium may lead to the use of anti VEGF therapy like
bevacizumab, in regressing local blood vessels and size of pterygium at a statistically
significant level. The therapeutic effects of bevacizumab are not
well understood to date mainly due to decrease in sample size and lack of
randomized control trials. The present aim of our study is to use anti
VEGF therapy in the treatment of primary pterygium in Pakistani population.
However the current study have shown statistically, no beneficial
effect of sub conjunctival bevacizumab (2.5 mg / 0.1 ml) on preventing the
recurrence of pterygium in given sample size over six months duration like
study done by Razeghinejad MR et al19. In this study they used a
total of 7.5 mg subconjunctival bevacizumab. 5 mg / 0.2 ml on the day of
surgery and 2.5 mg / 0.1 ml on the fourth day after surgery. This is comparable
to our study in which we used a total of 2.5 mg / 0.1 ml of bevacizumab for
only one time.
Although studies by Rashid Omar et al and Alhammami et al showed
that sub-conjunctival bevacizumab reduces size and recurrence rate of pterygium20,
21. Like our study, the researchers in their studies did not found
statistically significant ocular complications and allergies. Another researcher
Oguz et al in his study found decreased recurrence rate of pterygium22.
Mohammad-Reza et al, in their study found clinically significant effect of sub
conjunctival bevacizumab injection on pterygium recurrence but not
statistically 23.
The current study as seen in Table 04 did not observe any local
ocular complications and allergies statistically like ocular surface toxicity,
corneal abrasion, persistent epithelial defect and infection. This was really
an astonishing finding in contrast to finding of Kim et al 24, who
found spontaneous loss of epithelial integrity in excess percentage. In their
study, they used high concentration (1.25%) of bevacizumab topically twice
daily for two months. The findings are impactful as it is one time use and less
in complications. This clearly indicates that the safety of topical bevacizumab
is inversely proportional to the duration of the treatment.
So, from our study it is seen that single per operative subconjunctival
injection of bevacizumab can be safely used without significant ocular
complications and allergies. It decreases recurrence rate of primary pterygium,
but this decrease was not statistically significant.
More over bevacizumab has been observed in six human trials to be
safe during subconjunctival administration; it helps in halting fibrovascular
proliferative process by stopping G1 and G0 phase and initiating
apoptosis. Our current study showed effect of bevacizumab on pterygium
proliferation and recurrence is not significant statistically.
A recent study demonstrated no recurrence of pterygium in the
duration of six years of the subconjunctival bevacizumab injection while in the
current we have not observed such finding maybe due to the lesser duration of study.
In a study done by Hirst LW et al, he defined the time interval required to
follow the patients after pterygium excision to recurrence of the disease
should be acceptably one year25. In the current study, follow up period
was six months.
It is suggested that in future for promising and clarification of
results longer follow up and increased sample size is needed.
CONCLUSION
Bevacizumab injection given sub conjunctival, showed statistically
no significant effect on recurrence of pterygium and no significant adverse
effects.
Author’s Affiliation
Dr. Narain Das (ND)
MBBS, FCPS (OPHTHALMOLOGY)
Assistant Professor, SMBBMC Lyari, Karachi.
Dr. Shakir Zafar (SZ)
MBBS, FCPS (OPHTHALMOLOGY)
Associate
Professor United Medical & Dental College, Karachi.
Dr. Asma Shams (AS)
MBBS, FCPS (OPHTHALMOLOGY)
Senior Registrar, SMBBMC Lyari, Karachi.
Role of Authors
Dr. Narain Das
Performed all surgeries.
Dr. Shakir Zafar
Manuscript writing and Language
correction.
Dr. Asma Shams
Data collection and statistical analysis.
REFERENCES
1.
Kanski JJ. Conjunctiva. In kanski
JJ clinical ophthalmology 5th Edition New York Butterworth
Heinemann, 2003: 62-94.
2.
Di Girolamo N, Chui J, Coroneo MT, Wakefield D. Pathogenesis of pterygia: role of cytokines, growth factors, and
matrix metalloproteinase’s. Prog Retin Eye Res. 2004; 23: 195-228.
3.
Van Setten G, Aspiotis M, Blalock TD, Grotendorst G, Schultz G. Connective tissue growth factor in pterygium: simultaneous
presence with vascular endothelial growth factor-possible contributing factor
to conjunctival scarring. Graefes Arch Clin Exp Ophthalmol. 2003; 241: 135-139.
4.
Solomon A, Grueterich M, Li DQ, Meller D, Lee SB, et al. Over expression of Insulin-like growth factor –binding protein-2
in pterygium body fibroblasts. Invest Ophthalmol Vis Sci. 2003; 44: 573-580.
5.
Miani R, Collision DJ, Maidment JM, Davies PD, Wormstone IM. Pterygial derived fibroblasts express functionally active
histamine and epidermal growth factor receptors, Exp Eye Res. 2002; 74:
237-244.
6.
Jin J, Guan M, Sima J, Gao G, Zhang M, et al. Decreased pigment epithelium-derived factor and increased
vascular endothelial growth factor levels in pterygia. Cornea, 2003; 22:
473-477.
7.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J,
et al. Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med.
2004; 350: 2335-2342.
8.
Ang LP, Chua JL, Tan DT.
Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol.
2007; 18: 308-313.
9.
Frucht-Prey J, Raiskup F, Ilsar M, Landau D, Orucov F, Solomon A. Conjunctival autografting combined with low-dose mitomycin C for
prevention of primary pterygium recurrence. Am J Ophthalmol. 2006; 141: 1044-1050.
10.
Hirst LW. The treatment of pterygium.
Surv Ophthalmol. 2003; 48: 145-148.
11.
Ferrara N, Hillan KJ, Novotny W.
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer
therapy. Biochem Biophys Res Commun. 2005; 333 (2): 328-335.
12.
Mutlu FM, Sobaci G, Tatar T, Yildirim E. A comparative study of recurrent pterygium surgery: limbal
conjunctival autograft transplantation versus mitomycin C with conjunctival
flap. Ophthalmology, 1999; 106: 817-821.
13.
Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the
management of pterygia. Med Hypotheses, 2007; 69: 925-927.
14.
Meyer CH, Krohne TU, Holz FG.
Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg
versus 3.0 mg of bevacizumab in humans. Retina, 2011; 31: 1877-1884.
15.
Lekhanont K, Patarakittam T, Thongphiew P, Suwan-Apichon O,
Hanutsaha P. Randomized controlled trial of
subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot
study. Cornea, 2012; 31: 155-161.
16.
Enkvetchakul O, Thanathanee O, Rangsin R, Lekhanont K,
Suwan-Apichon O. A randomized controlled
trial of intralesional bevacizumab injection on primary pterygium: preliminary
results. Cornea, 2011; 30: 1213-1218.
17.
Krohne Tu, Eter N, Holz FG.
Meyer Ch. Intraocular pharmacokinetics of bevacizumab after a single
intravitreal injection in humans. Am J Ophthalmol. 2008; 146: 508-512.
18.
Tan DTH, Chee SP, Dear KBG, Lim AS. Effect of pterygium morphology on pterygium recurrence in a
controlled trial comparing conjunctival autografting with bare sclera excision.
Arch Ophthalmol. 1997; 115 (10): 1235-1240.
19.
Razeghinejad MR, Hosseini H, Ahmadi F, Rahat F, Eghbal H. Preliminary results of subconjunctival bevacizumab in primary
pterygium excision. Ophthalmic Res. 2010; 43: 134-138.
20.
Omar R, Rimsha S, Waseem R, Banday RA, Shahzada BS, Assif SI. Role of subconjunctival bevacizumab in treatment of pterygium,
Pak J Ophthalmol. 2012; Vol. 28 No. 3.
21.
Alhammami H, Farhood Q, Shuber H. subconjunctival bevacizumab injection in treatment of recurrent
pterygium, J Clin EXP Ophthalmol. 2013; 4: 267.
22.
Oguz H, Kilitc; oglu A, Yasar M.
Limbal conjunctival using autografting for preventive recurrences after
pterygium excision. Ophthalmol Res. 2010; 43: 134-8.
23.
Mohammad-Reza Razeghinejad, MD and Mohammad Banifatemi, MD. Subconjunctival bevacizumab for primary pterygium excision; J
Ophthalmic Vis Res. 2014; 9 (1): 22-23.
24.
Kim SW, Ha BJ, Kim EK, Tchan H, Km TI. The effect of topical bevacizumab on corneal neovascularization.
Ophthalmology, 2008; 115: e33-e38.
25.
Hirst
LW, Sebban A, Chant D. Pterygium recurrence time, ophthalmology, 1994; 101: 755-8.